
Top insights from the Endpoints at ASCO McKesson leadership panel
Guided by our values, we are an impact-driven organization that improves care in every setting – one product, one partner, one patient at a time.
Through our core commitments, we are leveraging our scale for the greater good, such as serving the needs of our stakeholders, donating back to our communities, protecting our planet, working with policymakers, and more.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportOur businesses bring together leading technologies, innovative solutions and hands-on expertise to support the entire healthcare ecosystem.
We distribute pharmaceuticals and medical supplies to healthcare settings across North America, from pharmacies and hospitals to doctors’ offices and clinics.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
We provide research, insights, technologies and other support to help address challenges in cancer and specialty care.
We provide a suite of solutions designed to address access, affordability and adherence challenges by bridging the gaps between biopharma companies, pharmacies, providers, and payers to help patients get on and stay on their medications.
We offer solutions that enable employers, payers, health-plan brokers and government agencies to provide lower-cost options for prescription medications and therapies.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportA visual exploration of our distribution preparation and deployment detail
Read time: 3 minutes
As an industry leader in vaccine distribution, McKesson is prepared to support the U.S. government through Operation Warp Speed to deliver Americans safe and effective COVID-19 vaccines as fast as possible. Earlier this year, the Centers for Disease Control and Prevention (CDC) designated our company as its centralized distribution partner for the U.S. COVID-19 Vaccination Program. And while this does not include the ultra-frozen Pfizer-BioNTech COVID-19 vaccine (the Pfizer vaccine), we will be distributing the Moderna vaccine and other future frozen and refrigerated vaccines once approved or authorized for emergency use by the U.S. Food and Drug Administration (FDA).
Yet, being ready to distribute vaccines is only part of the story. These vaccines also require ancillary supplies to administer them.
A few months ago, we partnered with the Strategic National Stockpile – part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services – to assemble ancillary supply kits for the multiple COVID-19 vaccine candidates in large-scale (Phase 3) clinical trials. Ever since, we’ve been heavily engaged in preparing new distribution centers (DCs) and assembling a team to build and send out the supply kits.
And now that the FDA has issued the first Emergency Use Authorization (EUA) for the Pfizer vaccine, we’ve started to ship out ancillary supply kits through our carrier partners to point-of-care facilities throughout the country.
Providing a Sense of Scale
McKesson set up dedicated DCs to support ancillary supply kit assembly and storage for the U.S. government.
We added more than 1.5 million square feet of DC space for supply kit assembling and storage. For comparison, that’s about the size of Grand Central Station in New York City. And we used 3.7 million pounds of steel to create the supply kit holding racks in just one of our DCs – roughly one-fifth as heavy as the Eiffel Tower.
Recruiting a New Workforce
To support this monumental effort, we engaged several hundred workers in less than two months. With this new workforce in place, the supply kit distribution centers were fully operational within a matter of weeks.
Ready to Go
We’ve spent months preparing for the moment COVID-19 vaccine(s) become available. In fact, prior to the FDA’s EUA of the first COVID-19 vaccine, we put together enough supply kits to support administration of more than 100 million doses.
Each ancillary supply kit, except for the kits designated for use with the Pfizer vaccine, includes:
Mixing kits are included in ancillary kits for the Pfizer vaccines that require reconstitution with diluent or mixing with adjuvant at the point of administration. The diluent is used to convert the ultra-frozen vaccine into a liquid form for administration.
The Details that Matter
For the refrigerated and frozen COVID-19 vaccines like Moderna’s, each kit includes the ancillary supplies needed to administer up to 100 doses of vaccine. The kits will usually be shipped at the same time and with the same carrier as the corresponding vaccine. For the ultra-frozen Pfizer COVID-19 vaccine, each supply kit supports 975 doses and is shipped using UPS.
Safety First
Protecting workers is crucial to the success of this critical effort. Safety measures are in place for everyone working at these McKesson DCs, which includes providing face masks and gloves, administering daily temperature checks, and maintaining social distancing. We also require regular use of hand sanitizer and cleaning wipes, which are located at stations throughout each DC.
Top insights from the Endpoints at ASCO McKesson leadership panel
Enhancing patient access and engagement in clinical trials.
Learn how InspiroGene is helping deliver revolutionary cell and gene therapies to patients in need.
Insights from the 2025 CoverMyMeds Medication Access Report, From Barriers to Bridges
For two years in a row, McKesson has partnered with customers and industry partners to bring health education and awareness of resources to members of the Navajo community.
Learn more about RxOwnership, McKesson’s strategic consultants who help independent pharmacy owners navigate challenges, optimize operations and achieve financial health.
Learn about McKesson’s new Cell and Gene Therapy (CGT) brand, InspiroGene, and the launch of a first-of-its-kind report about the CGT landscape and its future trajectory.
Milken Institute Future of Health Summit panelists address critical industry challenges and explore ways to futureproof the pharmaceutical supply chain.
Learn how pharmacists are transforming patient health across settings.
Learn how the CoverMyMeds Pharmacy dispensing network enhances patient care and streamlines prescription fulfillment.